ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2721

Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome

Sabrina Gmuca1, Maitry Sonagra 2, Rui Xiao 2, Elizabeth Mendoza 2, Kimberly S. Miller 3, Nina H. Thomas 1, Pamela F. Weiss 1, David D. Sherry 1 and Jeffrey Gerber 2, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, 3Children's Hospital fo Philadelphia, Philadelphia, PA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Chronic pain, cognitive dysfunction and clinical research, fibromyalgia, Pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Dyscognition, including loss of mental clarity and problems with attention and memory, often affects adolescents with juvenile fibromyalgia syndrome (JFMS). Our understanding of this neuropsychological symptom, however, is limited. It is unclear whether adolescents with JFMS experiencing subjective (or self-reported symptoms of) dyscognition have objectively measurable neurocognitive deficits. We aimed to determine 1) the prevalence of subjective and objective dyscognition and 2) the association between subjective and objective dyscognition among adolescents with JFMS.

Methods: We conducted a pilot, prospective cohort study of children ages 12-17 years diagnosed with JFMS according to 2010 ACR criteria for fibromyalgia syndrome seen in a pediatric rheumatology pain clinic from July 2017- February 2019. Exclusion criteria included non-English speaking patients, use of stimulant medication, or a condition precluding completion of assessments. Subjects completed both patient-reported outcomes (PROs) and neurocognitive testing. Subjects with poor effort based on the Memory Validity Profile (MVP) or Medical Symptoms Validity Test (MSVT) were excluded from objective dyscognition analyses. Subjective dyscognition was defined as a Pediatric Quality of Life Inventory (PedsQL) Cognitive Functioning Scale score ≤50 or self-reported Behavior Rating Inventory of Executive Function (BRIEF-2) global executive composite (GEC) score ≥ 70. Objective dyscognition was defined as impairment of more than two standard deviations in any of the domains in the neurocognitive battery. We assessed the association of clinical signs and symptoms with the presence of subjective dyscognition using Fisher-Exact test or Wilcoxon-rank test. The association between subjective and objective dyscognition was analyzed via Fisher-Exact test.

Results: Nineteen subjects met criteria and completed the study. Most subjects were female (79%), non-Hispanic (89%) and Caucasian (74%) (Table 1). Median age at enrollment was 15 years (IQR: 12.0-16.0). Sixty-three percent (n=12) of subjects reported subjective dyscognition and 44% (8/18) had objective dyscognition in ≥ 1 domain. Subjective dyscognition was associated with greater symptoms of anxiety, depression, lower resilience, lower health-related quality of life, greater fatigue, and poorer sleep (all p< 0.05; Table 1). The neurocognitive battery domains most commonly impaired included complex psychomotor speed (28%), attention (22%) and executive function (17%) (Table 2). The presence of subjective dyscognition was not significantly associated with objective dyscognition (all p > 0.05).

Conclusion: Sixty-three percent and 44% of adolescents with JFMS had subjective or objective dyscognition, respectively. Subjective dyscognition was not associated with objective dyscognition. This discrepancy may be due to the exacerbation of subjective dyscognition by co-morbid depression, anxiety and/or fatigue. As this study is ongoing, we anticipate that analyzation of additional data will help explain this discrepancy and also guide evidence-based recommendations for neuropsychological testing for JFMS.


ACR_table1


ACR_table2_2019


Disclosure: S. Gmuca, None; M. Sonagra, None; R. Xiao, None; E. Mendoza, None; K. Miller, None; N. Thomas, None; P. Weiss, None; D. Sherry, None; J. Gerber, None.

To cite this abstract in AMA style:

Gmuca S, Sonagra M, Xiao R, Mendoza E, Miller K, Thomas N, Weiss P, Sherry D, Gerber J. Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/subjective-and-objective-dyscognition-in-adolescents-with-juvenile-fibromyalgia-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subjective-and-objective-dyscognition-in-adolescents-with-juvenile-fibromyalgia-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology